← Back to Patent Explorer
US4677097A Expired / Lapsed US ⏱️ 0.0 years remaining

Compositions for inducing contractile motility of the gastrointestinal tract

Assignee: KITASATO KENKYUSHO 9-1 SHIROKANE 5-CHOME MINATO-KU TOKYO-TO JAPAN A NON-PROFIT JURIDICAL PERSON OF JAPAN
•
Filing: 1985-10-04
•
Granted: 1987-06-30
•
Expires: 2005-10-04
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A pharmaceutical composition for inducing contractile motility of the gastrointestinal tract in humans and animals, comprising as active ingredient 8,9-anhydroerythromycin 6,9-hemiketals, anhydroerythromycins, derivatives thereof and/or pharmaceutically acceptable salts thereof, in association with a pharmaceutically acceptable carrier or excipient. The active compounds may be produced by chemical modification of erythromycin and exhibit no or little antimicrobial activity. By administering the present composition to humans and animals, contractile motility of the gastrointestinal tract similar to the motility occurring naturally under normal conditions may be effectively induced.

Inventors

  • 👤 Satoshi Omura
  • 👤 Zen Itoh

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 12:40
CPC Classifications
C; C07; C07H; C07H17/00; C07H17/04; C07H17/08; A; A61; A61P; A61P1/00; A61P1/14

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 73 words
A method for inducing contractile motility of the gastrointestinal tract of an animal subject which comprises administering an effective amount of an active ingredient selected from the group consisting of 8,9-anhydroerythromycin A 6,9 hemiketal; 8,9 anhydroerythromycin B 6,9-hemiketal; 8,9-anhydroerythromicin C, 6,9-hemiketal; 8,9-anhydroerythromycin D, 6,9-hemiketal; 8,9-anhydroerythromycin F 6,9-hemiketal; anhydroerythromycin A, anhydroerythromycin C, anhydroerythromycin F; erythromycin derivatives thereof and pharmaceutically acceptable salts thereof; such active ingredient being admixed with a pharmaceutically acceptable carrier or excipient.
Claim 2
Independent Claim 73 words
A method for inducing contractile motility of the gastrointestinal tract of an animal subject which comprises administering an effective amount of an active ingredient selected from the group consisting of 8,9-anhydroerythromycin A 6,9 hemiketal; 8,9 anhydroerythromycin B 6,9-hemiketal; 8,9-anhydroerythromicin C, 6,9-hemiketal; 8,9-anhydroerythromycin D, 6,9-hemiketal; 8,9-anhydroerythromycin F 6,9-hemiketal; anhydroerythromycin A, anhydroerythromycin C, anhydroerythromycin F; erythromycin derivatives thereof and pharmaceutically acceptable salts thereof; such active ingredient being admixed with a pharmaceutically acceptable carrier or excipient.
Claim 3
Dependent Claim 34 words
The method of claim 1 wherein said active ingredient is administered by intravenous injection at a daily dosage of from about 0.001 mg/kg to about 10 mg/kg of body weight based on active ingredient.
Claim 4
Dependent Claim 30 words
The method of claim 1 wherein one composition is administered orally at a daily dosage of 5 to 10 times the range to 0.001 to 10 mg/kg of body weight.
Claim 5
Dependent Claim 38 words
The method of claim 1 wherein the derivative employed is an erythromycin derivative selected from the group consisting of ethylsuccinic acid esters, ethylcarbonic acid esters, glycopeptonates, stearic acid esters, propionic acid esters, lauric acid-propionic acid diesters and lactobionate.
Claim 6
Dependent Claim 27 words
The method of claim 1 wherein the composition is administered in a form selected from the group consisting of emulsion, hydrate, solution, powder, granules, capsules and tablets.
Claim 7
Dependent Claim 20 words
The method of claim 2 wherein said active ingredient is administered by intravenous injection at a dose of 1.0 mg/kg.

References Cited (Backward Citations)

US3681323A Cited
US3674773A Cited
US3816397A Cited
US3828022A Cited
US4053592A Cited
US3855200A Cited
US3963696A Cited
US4439426A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-06-29 1990-12-29 1991-06-30 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-06-29 1994-12-29 1995-06-30 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-06-29 1998-12-29 1999-06-30 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag